Literature DB >> 25557270

Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.

Choon-Young Kim1, Shin Young Jeong2, Gun Oh Chong3, Seung Hyun Son4, Ji-hoon Jung4, Do-Hoon Kim4, Sang-Woo Lee4, Byeong-Cheol Ahn4, Jaetae Lee4.   

Abstract

OBJECTIVE: This study aimed to evaluate the prognostic value of quantitative metabolic parameters measured on F-18 FDG PET/CT (FDG PET/CT) at the time of the first relapse in patients with relapsed epithelial ovarian cancer (EOC).
METHODS: Fifty-six relapsed EOC patients were retrospectively included. Quantitative metabolic parameters including maximum standardized uptake value (SUVmax), whole-body metabolic tumor volume (WBMTV), and whole-body total lesion glycolysis (WBTLG) were measured on FDG PET/CT at the time of the first relapse. Post-relapse survival (PRS) was calculated from the date of diagnosis of relapsed disease to the date of death or last follow-up. Univariate and multivariate analyses for PRS were performed using clinical and quantitative metabolic parameters.
RESULTS: Thirty-two patients died from the disease during the follow-up period (median: 46.2 months). On univariate and multivariate analyses, the platinum-free interval, type of second-line treatment, WBMTV, and WBTLG were all significant prognostic factors for PRS. The subgroup of patients who were platinum-sensitive with low WBMTV and low WBTLG showed better prognosis, when compared with other subgroups (log-rank test, p<0.001). Patients treated with secondary cytoreductive surgery (SCS) followed by second-line chemotherapy showed significantly longer duration of PRS than patients treated with second-line chemotherapy only (mean PRS=61 vs. 36 months, χ(2)=8.68, p=0.032).
CONCLUSION: Our results suggest that quantitative metabolic parameters measured on FDG PET/CT at the time of the first relapse have significant predictive values for PRS. Incorporating quantitative metabolic parameters and conventional clinical parameters has a superior prognostic discrimination compared with conventional clinical parameters alone.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  F-18 FDG PET/CT; Prognosis prediction; Relapsed epithelial ovarian cancer; Whole-body metabolic tumor volume; Whole-body total lesion glycolysis

Mesh:

Substances:

Year:  2014        PMID: 25557270     DOI: 10.1016/j.ygyno.2014.12.032

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

Authors:  Laura Evangelista; Anna Rita Cervino; Cristina Ghiotto; Tania Saibene; Silvia Michieletto; Bozza Fernando; Enrico Orvieto; Valentina Guarneri; Pierfranco Conte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-31       Impact factor: 9.236

2.  18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value.

Authors:  Shuai Liu; Zheng Feng; Hao Wen; Zhaoxia Jiang; Herong Pan; Yu Deng; Lei Zhang; Xingzhu Ju; Xiaojun Chen; Xiaohua Wu
Journal:  Jpn J Radiol       Date:  2018-06-25       Impact factor: 2.374

3.  Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.

Authors:  Federico Caobelli; Pierpaolo Alongi; Laura Evangelista; Maria Picchio; Giorgio Saladini; Marco Rensi; Onelio Geatti; Angelo Castello; Iashar Laghai; Cristina E Popescu; Carlotta Dolci; Cinzia Crivellaro; Silvia Seghezzi; Margarita Kirienko; Vincenzo De Biasi; Fabrizio Cocciolillo; Natale Quartuccio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-18       Impact factor: 9.236

Review 4.  Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.

Authors:  Mayur Virarkar; Dhakshinamoorthy Ganeshan; Anjalie Tara Gulati; Sarah Palmquist; Revathy Iyer; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11-11

Review 5.  What's New in Imaging for Gynecologic Cancer?

Authors:  Sairah R Khan; Mubarik Arshad; Kathryn Wallitt; Victoria Stewart; Nishat Bharwani; Tara D Barwick
Journal:  Curr Oncol Rep       Date:  2017-11-06       Impact factor: 5.075

6.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

Review 7.  Current update on malignant epithelial ovarian tumors.

Authors:  Sherif B Elsherif; Priya R Bhosale; Chandana Lall; Christine O Menias; Malak Itani; Kristina A Butler; Dhakshinamoorthy Ganeshan
Journal:  Abdom Radiol (NY)       Date:  2021-06-05

8.  Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [18F]FDG PET/CT volumetric parameters and tumour markers HE4 and CA125.

Authors:  Ariel Glickman; Pilar Paredes; Núria Carreras-Diéguez; Aida Niñerola-Baizán; Lydia Gaba; Jaume Pahisa; Pere Fusté; Marta Del Pino; Berta Díaz-Feijóo; Eduardo González-Bosquet; Núria Agustí; Nuria Sánchez-Izquierdo; David Fuster; Andrés Perissinotti; Inmaculada Romero; Esther Fernández-Galán; Josep Lluís Carrasco; Blanca Gil-Ibáñez; Aureli Torné
Journal:  Eur Radiol       Date:  2021-09-29       Impact factor: 7.034

9.  CONSORT-Independent prognostic value of asphericity of pretherapeutic F-18 FDG uptake by primary tumors in patients with breast cancer.

Authors:  Ji-Hoon Jung; Seung Hyun Son; Do-Hoon Kim; Jeeyeon Lee; Shin Young Jeong; Sang-Woo Lee; Ho Yong Park; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

10.  Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up.

Authors:  Daniela Rusu; Thomas Carlier; Mathilde Colombié; Dorothée Goulon; Vincent Fleury; Nicolas Rousseau; Dominique Berton-Rigaud; Isabelle Jaffre; Françoise Kraeber-Bodéré; Loic Campion; Caroline Rousseau
Journal:  Front Med (Lausanne)       Date:  2015-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.